Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.
4/5 보강
TL;DR
The partial regrowth achieved in 4 of 5 patients and the recruitment of TReg cells in lesional skin support the interest of promoting Treg cells for treating AA, and further investigations are now required to confirm and to optimize the design in order to enhance the Treg cell response.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
5 patients with severe AA resistant to previous systemic treatments.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Further investigations are now required to confirm and to optimize the design in order to enhance the Treg cell response. [TRIAL REGISTRATION] clinicaltrials.gov Identifier: NCT01840046.
📑 코퍼스 인용 관계
· 인용됨 28
📑 인용한 논문 (6) ▾
- Stem cell-based therapies for alopecia areata: a narrative review. Stem cell research & therapy · 2026
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies. MedComm · 2025
- Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment:… Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia… Journal of cosmetic dermatology · 2025
- Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine. Skin appendage disorders · 2025
- Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic … Annals of dermatology · 2023
연도별 인용 (2014–2026) · 합계 221
OpenAlex 토픽 ·
Hair Growth and Disorders
Dermatology and Skin Diseases
Mast cells and histamine
Abstract 🌐 Abstract
[IMPORTANCE] An impaired inhibitory function of circulating CD4+CD25+ regulatory T (Treg) cells was reported to play a key role in alopecia areata (AA). We report the first use to our knowledge of low-dose interleukin 2 for treating severe AA by promoting the recruitment of Treg cells.
[OBSERVATIONS] We conducted a prospective open pilot study in 5 patients with severe AA resistant to previous systemic treatments. Subcutaneous interleukin 2 (1.5 million IU/d) was administered during 5 days, followed by three 5-day courses of 3 million IU/d at weeks 3, 6, and 9. The primary outcome was the evolution of the Severity of Alopecia Tool (SALT) score, evaluated by 2 independent investigators on standardized photographs. Lesional skin biopsy specimens and peripheral blood lymphocyte phenotype were analyzed. The median SALT score went from 82 (range, 63-100) at baseline to 69 (range, 28-100) at 6 months. Immunochemical analysis revealed the appearance or a notable increase in Treg cell count in 4 of 5 patients at the end of the treatment compared with baseline. No serious adverse event was reported.
[CONCLUSIONS AND RELEVANCE] The partial regrowth achieved in 4 of 5 patients and the recruitment of Treg cells in lesional skin support the interest of promoting Treg cells for treating AA. Further investigations are now required to confirm and to optimize the design in order to enhance the Treg cell response.
[TRIAL REGISTRATION] clinicaltrials.gov Identifier: NCT01840046.
[OBSERVATIONS] We conducted a prospective open pilot study in 5 patients with severe AA resistant to previous systemic treatments. Subcutaneous interleukin 2 (1.5 million IU/d) was administered during 5 days, followed by three 5-day courses of 3 million IU/d at weeks 3, 6, and 9. The primary outcome was the evolution of the Severity of Alopecia Tool (SALT) score, evaluated by 2 independent investigators on standardized photographs. Lesional skin biopsy specimens and peripheral blood lymphocyte phenotype were analyzed. The median SALT score went from 82 (range, 63-100) at baseline to 69 (range, 28-100) at 6 months. Immunochemical analysis revealed the appearance or a notable increase in Treg cell count in 4 of 5 patients at the end of the treatment compared with baseline. No serious adverse event was reported.
[CONCLUSIONS AND RELEVANCE] The partial regrowth achieved in 4 of 5 patients and the recruitment of Treg cells in lesional skin support the interest of promoting Treg cells for treating AA. Further investigations are now required to confirm and to optimize the design in order to enhance the Treg cell response.
[TRIAL REGISTRATION] clinicaltrials.gov Identifier: NCT01840046.
The partial regrowth achieved in 4 of 5 patients and the recruitment of TReg cells in lesional skin support the interest of promoting Treg cells for treating AA, and further investigations are now req
APA 7
Castela, E., F, L. D., Butori, C., Ticchioni, M., Hofman, P., Bahadoran, P., Lacour, J. P., & Passeron, T. (2014). Effects of low-dose recombinant interleukin 2 to promote t-regulatory cells in alopecia areata.. JAMA dermatology, 150(7), 748-51. https://doi.org/10.1001/jamadermatol.2014.504
Vancouver
Castela E, F LD, Butori C, Ticchioni M, Hofman P, Bahadoran P, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA dermatology. 2014;150(7):748-51. doi:10.1001/jamadermatol.2014.504
AMA 11
Castela E, F LD, Butori C, Ticchioni M, Hofman P, Bahadoran P, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA dermatology. 2014;150(7):748-51. doi:10.1001/jamadermatol.2014.504
Chicago
Castela, E., F, L. D., Butori, C., Ticchioni, M., Hofman, P., Bahadoran, P., Lacour, J. P., and Passeron, T.. 2014. "Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata." JAMA dermatology 150 (7): 748-51. https://doi.org/10.1001/jamadermatol.2014.504
MLA 9
Castela, E., et al. "Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata." JAMA dermatology, vol. 150, no. 7, 2014, pp. 748-51. doi:10.1001/jamadermatol.2014.504.
PMID
24872229 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 20
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
- Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation.
- Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options.
- Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunctio…
- The role of lymphocytes in the development and treatment of alopecia areata.
- Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strate…
- Alopecia Areata: Current Treatments and New Directions.
- Alopecia Areata: An Autoimmune Disease of Multiple Players.
- Immune modulation of hair follicle regeneration.
- Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restrictio…
- Novel potential therapeutic targets of alopecia areata.
- The current state of knowledge of the immune ecosystem in alopecia areata.
- New and Emerging Therapies for Alopecia Areata.
- Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ…
- Serum concentrations of selected proinflammatory cytokines in children with alopecia areata.
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies.
- Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopeci…
- The Changing Landscape of Alopecia Areata: The Translational Landscape.
- Regulatory T cells in skin.
- The potential of regulatory T cell-based therapies for alopecia areata.